Cover Image
市場調查報告書

細胞毒性T淋巴球蛋白質4 (CTLA-4,CD152) :開發中產品分析

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 363120
出版日期 內容資訊 英文 141 Pages
訂單完成後即時交付
價格
Back to Top
細胞毒性T淋巴球蛋白質4 (CTLA-4,CD152) :開發中產品分析 Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H1 2018
出版日期: 2018年02月13日 內容資訊: 英文 141 Pages
簡介

本報告提供細胞毒性T淋巴球蛋白質4 (CTLA-4,CD152)的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

開發中的產品:各大學/研究機關

治療藥的評估

  • 單劑/聯合治療別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Aduro BioTech, Inc.
  • Agenus, Inc.
  • Alligator Bioscience AB
  • AlphaMab Co., Ltd
  • CytomX Therapeutics, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • JHL Biotech, Inc.
  • Lytix Biopharma AS
  • Novartis AG
  • OncoImmune, Inc.
  • Pfizer Inc.
  • Premier Biomedical Inc.
  • PsiOxus Therapeutics Limited
  • Sutro Biopharma, Inc.

藥物簡介

暫停的計劃

最新消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1291TDB

Summary

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses.

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 43 molecules. Out of which approximately 42 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 5, 4, 1, 18, 9 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Gastric Cancer, Bladder Cancer, Breast Cancer, Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Small-Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anaplastic Thyroid Cancer, Cervical Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastroesophageal (GE) Junction Carcinomas, Germ Cell Tumors, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Muscle Invasive Bladder Cancer (MIBC), Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Hodgkin Lymphoma, Peritoneal Cancer, Renal Cell Carcinoma, Adrenal Gland Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Dedifferentiated Liposarcoma, Dysgerminoma, Endometrial Cancer, Ependymoma, Esophageal Cancer, Ewing Sarcoma, Germinomatous (Seminomatous) Germ Cell Tumors, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kaposi Sarcoma, Lymphoma, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medullary Thyroid Cancer, Medulloblastoma, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Neuroblastoma, Neuroendocrine Tumors, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Salivary Gland Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Ureter Cancer, Urethral Cancer, Urinary Tract Cancer, Vaginal Cancer and Vulvar Cancer.

The latest report Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
  • The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Overview
    • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development
    • Aduro BioTech Inc
    • Agenus Inc
    • Alligator Bioscience AB
    • Bristol-Myers Squibb Co
    • Cold Genesys Inc
    • Crown Bioscience Inc
    • Five Prime Therapeutics Inc
    • GigaGen Inc
    • Immunocore Ltd
    • Immunwork Inc
    • Innovent Biologics Inc
    • JHL Biotech Inc
    • MacroGenics Inc
    • MedImmune LLC
    • Merck & Co Inc
    • OncoImmune Inc
    • PharmAbcine Inc
    • Premier Biomedical Inc
    • Replimune Ltd
    • Serometrix LLC
    • Sutro Biopharma Inc
    • Tikcro Technologies Ltd
    • Xencor Inc
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles
    • 10B-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADU-1604 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGEN-1884 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AGEN-2041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit CTLA4 for Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATOR-1015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic to Antagonize CTLA4 for Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody to Antagonize CTLA-4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody to Inhibit PD L1 and CTLA4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986218 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986249 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-0070 + Immune Checkpoint Modulator - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-0161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNC-225 + CNC-118 + Anti-CTLA-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab + IMCgp-100 + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • durvalumab + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FPT-155 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBI-310 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ipilimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ipilimumab + nivolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JMW-3B3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KN-044 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-3617 + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGD-019 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-1308 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize 1 PD-1 and CTLA-4 for Solid Tumor and Hematological Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize CTLA-4 for Metastatic Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize CTLA-4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize CTLA4 for Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CTLA4 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONC-392 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Antagonize CTLA4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CTLA4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tavolimab + tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TE-1254 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tremelimumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XmAb-20717 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XmAb-22841 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Products
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products
  • Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 25, 2018: Alligator Bioscience contracts Theradex Oncology as clinical CRO for the forthcoming Phase I study with ATOR-1015
      • Jan 22, 2018: European Commission Approves Bristol-Myers Squibb's Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
      • Jan 22, 2018: Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)
      • Jan 20, 2018: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer
      • Dec 29, 2017: CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia
      • Dec 18, 2017: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Yervoy (ipilimumab) for the Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
      • Dec 15, 2017: CHMP Adopts Positive Opinion for Yervoy
      • Dec 13, 2017: U.S. Food and Drug Administration Accepts Bristol-Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma and Grants Priority Review
      • Nov 28, 2017: CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic
      • Nov 28, 2017: European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma
      • Nov 10, 2017: Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604
      • Nov 10, 2017: MacroGenics To Present Poster on MGD019 at 32nd Annual SITC Meeting 2017
      • Nov 09, 2017: Agenus To Present on Lead Antibody Program AGEN1884 (CTLA-4) at SITC 2017
      • Nov 08, 2017: Xencor Presents Preclinical Data on Tumor Microenvironment Targeting Bispecific XmAb20717 At Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
      • Nov 07, 2017: Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018
  • Number of Products under Development by Indications, H1 2018 (Contd..4), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1)
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..4), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..5), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..6), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..7), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..8), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..9), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..10), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Aduro BioTech Inc, H1 2018
  • Pipeline by Agenus Inc, H1 2018
  • Pipeline by Alligator Bioscience AB, H1 2018
  • Pipeline by Bristol-Myers Squibb Co, H1 2018
  • Pipeline by Cold Genesys Inc, H1 2018
  • Pipeline by Crown Bioscience Inc, H1 2018
  • Pipeline by Five Prime Therapeutics Inc, H1 2018
  • Pipeline by GigaGen Inc, H1 2018
  • Pipeline by Immunocore Ltd, H1 2018
  • Pipeline by Immunwork Inc, H1 2018
  • Pipeline by Innovent Biologics Inc, H1 2018
  • Pipeline by JHL Biotech Inc, H1 2018
  • Pipeline by MacroGenics Inc, H1 2018
  • Pipeline by MedImmune LLC, H1 2018
  • Pipeline by Merck & Co Inc, H1 2018
  • Pipeline by OncoImmune Inc, H1 2018
  • Pipeline by PharmAbcine Inc, H1 2018
  • Pipeline by Premier Biomedical Inc, H1 2018
  • Pipeline by Replimune Ltd, H1 2018
  • Pipeline by Serometrix LLC, H1 2018
  • Pipeline by Sutro Biopharma Inc, H1 2018
  • Pipeline by Tikcro Technologies Ltd, H1 2018
  • Pipeline by Xencor Inc, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top